BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21422499)

  • 1. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders.
    Naramura M; Nadeau S; Mohapatra B; Ahmad G; Mukhopadhyay C; Sattler M; Raja SM; Natarajan A; Band V; Band H
    Oncotarget; 2011 Mar; 2(3):245-50. PubMed ID: 21422499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases.
    Mohapatra B; Ahmad G; Nadeau S; Zutshi N; An W; Scheffe S; Dong L; Feng D; Goetz B; Arya P; Bailey TA; Palermo N; Borgstahl GE; Natarajan A; Raja SM; Naramura M; Band V; Band H
    Biochim Biophys Acta; 2013 Jan; 1833(1):122-39. PubMed ID: 23085373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.
    Bandi SR; Brandts C; Rensinghoff M; Grundler R; Tickenbrock L; Köhler G; Duyster J; Berdel WE; Müller-Tidow C; Serve H; Sargin B;
    Blood; 2009 Nov; 114(19):4197-208. PubMed ID: 19734451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.
    Belizaire R; Koochaki SHJ; Udeshi ND; Vedder A; Sun L; Svinkina T; Hartigan C; McConkey M; Kovalcik V; Bizuayehu A; Stanclift C; Schenone M; Carr SA; Padron E; Ebert BL
    Blood; 2021 Apr; 137(16):2209-2220. PubMed ID: 33512474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation.
    Buetow L; Tria G; Ahmed SF; Hock A; Dou H; Sibbet GJ; Svergun DI; Huang DT
    BMC Biol; 2016 Sep; 14(1):76. PubMed ID: 27609087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapidly fatal myeloproliferative disorders in mice with deletion of Casitas B-cell lymphoma (Cbl) and Cbl-b in hematopoietic stem cells.
    Naramura M; Nandwani N; Gu H; Band V; Band H
    Proc Natl Acad Sci U S A; 2010 Sep; 107(37):16274-9. PubMed ID: 20805496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cbl family proteins: ring leaders in regulation of cell signaling.
    Swaminathan G; Tsygankov AY
    J Cell Physiol; 2006 Oct; 209(1):21-43. PubMed ID: 16741904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
    Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
    Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of function Cbl-c mutations in solid tumors.
    Daniels SR; Liyasova M; Kales SC; Nau MM; Ryan PE; Green JE; Lipkowitz S
    PLoS One; 2019; 14(7):e0219143. PubMed ID: 31260484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.
    Aranaz P; Hurtado C; Erquiaga I; Miguéliz I; Ormazábal C; Cristobal I; García-Delgado M; Novo FJ; Vizmanos JL
    Haematologica; 2012 Aug; 97(8):1234-41. PubMed ID: 22315494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
    Ahmed SF; Buetow L; Gabrielsen M; Lilla S; Sibbet GJ; Sumpton D; Zanivan S; Hedley A; Clark W; Huang DT
    Oncogene; 2021 Mar; 40(12):2149-2164. PubMed ID: 33627783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
    Sanada M; Suzuki T; Shih LY; Otsu M; Kato M; Yamazaki S; Tamura A; Honda H; Sakata-Yanagimoto M; Kumano K; Oda H; Yamagata T; Takita J; Gotoh N; Nakazaki K; Kawamata N; Onodera M; Nobuyoshi M; Hayashi Y; Harada H; Kurokawa M; Chiba S; Mori H; Ozawa K; Omine M; Hirai H; Nakauchi H; Koeffler HP; Ogawa S
    Nature; 2009 Aug; 460(7257):904-8. PubMed ID: 19620960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins.
    Nadeau S; An W; Palermo N; Feng D; Ahmad G; Dong L; Borgstahl GE; Natarajan A; Naramura M; Band V; Band H
    Biochem Anal Biochem; 2012 Jul; Suppl 6(1):. PubMed ID: 23997989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-β signaling.
    Kang JM; Park S; Kim SJ; Hong HY; Jeong J; Kim HS; Kim SJ
    Oncogene; 2012 Dec; 31(50):5123-31. PubMed ID: 22310290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
    Lv K; Jiang J; Donaghy R; Riling CR; Cheng Y; Chandra V; Rozenova K; An W; Mohapatra BC; Goetz BT; Pillai V; Han X; Todd EA; Jeschke GR; Langdon WY; Kumar S; Hexner EO; Band H; Tong W
    Genes Dev; 2017 May; 31(10):1007-1023. PubMed ID: 28611190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
    Merlinsky TR; Levine RL; Pronier E
    Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD2-associated protein (CD2AP) enhances casitas B lineage lymphoma-3/c (Cbl-3/c)-mediated Ret isoform-specific ubiquitination and degradation via its amino-terminal Src homology 3 domains.
    Calco GN; Stephens OR; Donahue LM; Tsui CC; Pierchala BA
    J Biol Chem; 2014 Mar; 289(11):7307-19. PubMed ID: 24425877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
    Schnittger S; Bacher U; Alpermann T; Reiter A; Ulke M; Dicker F; Eder C; Kohlmann A; Grossmann V; Kowarsch A; Kern W; Haferlach C; Haferlach T
    Haematologica; 2012 Dec; 97(12):1890-4. PubMed ID: 22733026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
    Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of c-Cbl in myeloid malignancies.
    Katzav S; Schmitz ML
    Oncotarget; 2015 May; 6(13):10689-96. PubMed ID: 26028666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.